ABVC BioPharma furnishes Q3 2025 results press release via 8-K

Q: How is the Item 2.02 information treated under the Exchange Act?

It is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act.

Q: Which period does the press release cover for ABVC?

It covers the third quarter ended September 30, 2025.

Q: What exhibits are included with this ABVC 8-K?

The filing includes Exhibit 99.1 (Press Release) and Exhibit 104 (Cover Page Inline XBRL data file).

Q: Does the 8-K constitute an offer to sell ABVC securities?

No. It expressly states it is not an offer to sell or the solicitation of an offer to buy securities.

Q: Where is ABVC’s common stock listed?

ABVC’s common stock trades on The Nasdaq Stock Market LLC under the symbol ABVC.

Q: Who signed the 8-K for ABVC?

It was signed by Uttam Patil, Chief Executive Officer.

ABVC BioPharma furnished an 8-K to announce its financial results for the third quarter ended September 30, 2025.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

ABVC BioPharma furnished an 8-K to announce its financial results for the third quarter ended September 30, 2025. The company reported these results via a press release attached as Exhibit 99.1.

The disclosure under Item 2.02 is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act. The filing also includes Exhibit 104, the cover page interactive data file formatted in Inline XBRL. The notice states it is not an offer to sell or solicit purchases of securities.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ABVC (ABVC) disclose in this 8-K?

ABVC furnished a press release announcing its financial results for the third quarter ended September 30, 2025, attached as Exhibit 99.1.

How is the Item 2.02 information treated under the Exchange Act?

It is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act.

Which period does the press release cover for ABVC?

It covers the third quarter ended September 30, 2025.

What exhibits are included with this ABVC 8-K?

The filing includes Exhibit 99.1 (Press Release) and Exhibit 104 (Cover Page Inline XBRL data file).

Does the 8-K constitute an offer to sell ABVC securities?

No. It expressly states it is not an offer to sell or the solicitation of an offer to buy securities.

Where is ABVC’s common stock listed?

ABVC’s common stock trades on The Nasdaq Stock Market LLC under the symbol ABVC.

Who signed the 8-K for ABVC?

It was signed by Uttam Patil, Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 11/03/2025 - 07:30 AM EST

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 3, 2025

ABVC BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

Nevada		001-40700		26-0014658
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

44370 Old Warm Springs Blvd.

Fremont, CA

94538

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number including area code: (510) 668-0881

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol		Name of each exchange on which registered
Common Stock, par value $0.001 per share		ABVC		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 3, 2025, ABVC BioPharma, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information reported under this Item 2.02 of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Neither this Current Report on Form 8-K, nor any exhibit attached hereto, is an offer to sell or the solicitation of an offer to buy the Securities described herein. Such disclosure does not constitute an offer to sell, or the solicitation of an offer to buy nor shall there be any sales of the Company’s securities in any state in which such an offer, solicitation or sale would be unlawful. The securities mentioned herein have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the Securities Act and applicable state securities laws.

Item 9.01 Exhibits

(d) Exhibits

Exhibit No.		Description
99.1		Press Release
104		Cover Page Interactive Data File, formatted in Inline XBRL

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ABVC BioPharma, Inc.

November 3, 2025	By:	/s/ Uttam Patil
		Uttam Patil
		Chief Executive Officer

Source: View Original Filing on SEC EDGAR